Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Lloyd M. Smith
Wake Forest University Health Sciences, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
GWC Technologies
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
An outside activity has a nexus with an individual's research activities if the outside activity arises from, relies upon or is related to the academic expertise that qualifies that individual to participate in federally funded research or human subjects research. The Institution has reasonably determined that the significant financial interest could directly and significantly affect the design, conduct, or reporting of the PHS-funded research and so requires management.
Functional characterization of regulatory sequence variants in complex diseases
Recent large-scale genetic studies have uncovered a large number of sequence variants that affect common diseases such as obesity and cardiovascular disease by altering the expression of individual genes. Unfortunately, current technologies to functionally characterize these sequence variants are not sufficient to verify these findings, and help understand the cellular mechanisms contributing to these disorders. We propose to develop three independent complementary technologies to accelerate and improve the in vitro high- throughput screening, in silico prediction, and in vivo validation of the effect of sequence variants on protein- DNA interactions and gene expression.
Filed on November 20, 2017.
Tell us what you know about Lloyd M. Smith's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Lloyd M. Smith”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Lloyd M. Smith | Texas Biomedical Research Institute | Conflict of Interest | GenTel BioSciences | Value cannot be readily determined |
| Lloyd M. Smith | Texas Biomedical Research Institute | Conflict of Interest | Apartia Pharmaceuticals | $0 - $4,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.